Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
Adding carfilzomib to lenalidomide improved survival in multiple myeloma patients after stem cell transplant
In a phase 3 trial of 180 patients with newly diagnosed multiple myeloma after autologous HSCT, carfilzomib-lenalidomide-dexamethasone maint…
Adding carfilzomib to lenalidomide after stem cell transplant boosted four-year survival to 67.5% compared to 38.0% for patients on lenalido…
Systemic glucocorticoid exposure in children linked to reversible myocardial hypertrophy, subclinical cardiac changes
Review finds reversible heart changes in children taking certain steroid medications
A narrative review of pediatric systemic glucocorticoid exposure found the most consistent structural signal is time-locked, reversible myoc…
Certain steroid medicines used for childhood illnesses can temporarily thicken the heart muscle in very young babies, but this change appear…
Topical dexamethasone mouthwash reduces oral mucositis severity in head and neck cancer radiotherapy patients
Can a simple mouthwash prevent the painful mouth sores of cancer radiation?
A phase II randomized controlled trial of 50 patients with head and neck cancer receiving ≥60 Gy radiotherapy found prophylactic topical dex…
Rinsing with a steroid mouthwash during head and neck cancer radiation reduced severe mouth sores, delayed pain peaks, and prevented the wor…
Observational report describes racial and ethnic disparities in receiving COVID-19 treatment medications in the US
Report describes racial and ethnic disparities in receiving COVID-19 treatment medications
An observational report from the United States described racial and ethnic disparities in the receipt of medications for COVID-19 treatment.
A new report describes racial and ethnic disparities in receiving medications for COVID-19 treatment in the United States.
Real-world study shows lenalidomide-dexamethasone yields 22.9-month PFS in transplant-ineligible myeloma
Real-world study shows lenalidomide treatment outcomes for older multiple myeloma patients
A prospective, non-interventional study of 168 transplant-ineligible NDMM patients in Germany found median PFS of 22.9 months and OS of 58.1…
Real-world data shows lenalidomide plus low-dose dexamethasone keeps older multiple myeloma patients disease-free for nearly two years while…
Antenatal dexamethasone reduces respiratory support need in late preterm infants in Vietnamese RCT
Can a steroid shot before late preterm birth help babies breathe easier?
A randomized controlled trial of 294 pregnant women at risk of late preterm delivery in Vietnam found antenatal dexamethasone reduced infant…
Giving mothers a steroid shot before late preterm birth cut the need for breathing support in babies by nearly 10%, reducing hospital stays …
Perineural dexamethasone extends analgesia duration in upper limb surgery blocks versus bupivacaine alone
Can a common steroid make pain relief from arm surgery last longer?
A double-blinded RCT in 90 ASA I/II patients undergoing upper limb procedures found adding 4 mg perineural dexamethasone to bupivacaine sign…
Adding a tiny amount of common steroid dexamethasone to arm surgery numbing shots nearly doubled pain relief time to over 20 hours with few …
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…